Table 3.

Summary of the meta-analysis results.

Categories	Trials (patients)	HR (95%CI)	I2 (%)	P h	Z	P z	P m
OS (All)	15 (1570)	1.81 (1.50–2.19)	42.3	.042	6.10	<.001
Cancer type							.698
Digestive system	4 (398)	1.43 (1.22–1.67)F	49.6	.114	4.39	<.001
HNC	3 (244)	2.05 (1.38–3.05)F	0.0	.642	3.54	<.001
BC	2 (272)	1.40 (0.96–2.04)F	0.0	.582	1.73	.084
OC	2 (206)	3.03 (1.77–5.16)F	0.0	.512	4.07	<.001
NSCLC	2 (309)	1.58 (1.18–2.13)F	0.0	.720	3.06	.002
RCC	2 (141)	4.37 (0.43–43.97)	82.3	.018	1.25	.211
Clinical stage							.267
Stage I-IV	12 (1248)	1.58 (1.39–1.79)F	32.8	.128	7.02	<.001
Stage I-III	2 (272)	1.40 (0.96–2.04)F	0.0	.582	1.73	.084
NR	1 (50)	15.76 (2.94–84.59)	-	-	3.22	.001
Sample size							.393
≥100	9 (1114)	1.53 (1.34–1.75)F	45.7	.064	6.20	<.001
<100	6 (456)	1.75 (1.34–2.27)F	43.1	.118	4.16	<.001
CRYAB-high (%)							.306
≥50%	10 (1049)	1.54 (1.34–1.77)F	42.7	.073	6.17	<.001
<50%	5 (521)	1.75 (1.21–2.55)	51.2	.085	2.95	.003
Analysis method							.174
Multivariate	13 (1433)	1.91 (1.54–2.38)	49.0	.024	5.78	<.001
Univariate	2 (137)	1.42 (0.96–2.11)F	0.0	.497	1.76	.078
DFS (All)	6 (4457)	1.47 (1.16–1.86)	62.6	.020	3.19	.001
DSS (All)	3 (4403)	1.40 (1.19–1.63)F	1.0	.364	4.15	<.001